Naringin protects human nucleus pulposus cells against TNF-α-induced inflammation, oxidative stress, and loss of cellular homeostasis by enhancing autophagic flux via AMPK/SIRT1 activation

Renchang Chen, Shang Gao, Huapeng Guan, Xin Zhang, Yuliang Gao, Youxiang Su, Yun Song, Yuehua Jiang, and Nianhu Li

1 Shandong University of Traditional Chinese Medicine, Jinan 250355, China
2 Spinal Department of Orthopedics, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China
3 Central Laboratory of Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China

Correspondence should be addressed to Nianhu Li; tigerlee073@126.com

Received 6 May 2021; Revised 26 November 2021; Accepted 1 February 2022; Published 27 February 2022

Abstract

Activation of the proinflammatory-associated cytokine, tumor necrosis factor-α (TNF-α), in nucleus pulposus (NP) cells is essential for the pathogenesis of intervertebral disc degeneration (IDD). Restoring autophagic flux has been shown to effectively protect against IDD and is a potential target for treatment. The goal of this study was to explore particular autophagic signalings responsible for the protective effects of naringin, a known autophagy activator, on human NP cells. The results showed that significantly increased autophagic flux was observed in NP cells treated with naringin, with pronounced decreases in the inflammatory response and oxidative stress, which rescued the disturbed cellular homeostasis induced by TNF-α activation. Autophagic flux inhibition was detectable in NP cells cotreated with 3-methyladenine (3-MA, an autophagy inhibitor), partially offsetting naringin-induced beneficial effects. Naringin promoted the expressions of autophagy-associated markers via SIRT1 (silent information regulator-1) activation by AMPK (AMP-activated protein kinase) phosphorylation. Either AMPK inhibition by BML-275 or SIRT1 silencing partially counteracted naringin-induced autophagic flux enhancement. These findings indicate that naringin boosts autophagic flux through SIRT1 upregulation via AMPK activation, thus protecting NP cells against inflammatory response, oxidative stress, and impaired cellular homeostasis. Naringin can be a promising inducer of restoration autophagic flux restoration for IDD.

1. Introduction

Intervertebral disc (IVD) is a composite tissue, composed of the inner nucleus pulposus (NP) and the outer annulus fibrosus [1]. NP cells are the predominant cell type within NP and control the metabolism in the extracellular matrix (ECM) of gelatinous NP by producing type II collagen (collagen II) and aggrecan, which are vital in resistance to compressive axial forces and pressure on the spine [1, 2].

Intervertebral disc degeneration (IDD) is a multi-factorial musculoskeletal disorder characterized by metabolic and structural changes that incrementally lead to the loss of IVD structural integrity and functions [3, 4]. It is estimated that IDD can be identified in roughly 40% of low back pain (LBP) patients [4] and is considered a significant contributor to the disease [5]. Moreover, the years lived with disability caused by LBP have been raised to 54% in 2015 from 1990, primarily attributed to population increase and ageing [6]. With this trend in demographic characteristics, the incidence of
 IDD will be likely to increase exponentially [7]. New treatment strategies for IDD have been studied for many years with limited achievements, due to unclear mechanisms for pathogenesis, which pose a challenge to effective precaution.

 IDD has been proven to be involved in aberrant NP cell behavior stimulated by inflammatory cytokines [8–10]. Among them, TNF-α is most critical as it triggers a proinflammatory cascade [11], leading to mitochondrial dysfunction, elevated reactive oxygen species (ROS) in a dynamic equilibrium, and the resultant enhancement of oxidative stress in NP cells [12]. Persistent oxidative stress stimulates excessive catabolic enzyme accumulation [13], ECM degradation, cell phenotypic diversification, and even cell apoptosis [14]. All these constitute a complicated ROS-sensitive signaling network.

 Macrouphagy is an evolutionarily conserved stress-responsive process that disposes unusual or damaged cytoplasmic organelles (e.g., damaged mitochondria) released from double-membrane vesicles (autophagosomes) and transports them to lysosomes for degradation, producing nutrients that contribute energy for cell metabolism [15]. Autophagic flux is a complete, dynamic process of autophagosome formation and fusion with lysosomes, cargo degradation, and the release of degradation products [11] in response to undernutrition, growth factor deficiency, hypoxia, infection, and other circumstances threatening cell survival. The overexpression of autophagy-associated markers is found to fuel cell apoptosis [16], which are critical targets for cell rescue. Some downstream components of the AMPK-activated protein kinase (AMPK) signaling have been proven to have various roles, including an autophagic effect, in mitochondrial homeostasis [17, 18]. Among others, silent information regulator-1 (SIRT1) activated by AMPK is involved in the regulation of physiological and pathological cell processes like mitochondrial function [19], inflammation, cell apoptosis [20], and autophagy [21]. Therefore, the AMPK/SIRT1 signaling may serve as a potential target for IDD treatment.

 Naringin, a major flavonoid identified in grapefruit, has been found to possess a wide variety of pharmacological properties including antioxidative, anti-inflammatory, and antiapoptotic effects [22–24], which are associated with restoration of the autophagic flux. In this study, we aimed to explore autophagic signalings responsible for those benefits of naringin’s effects on TNF-α-treated NP cells—an in-vitro IDD model.

2. Materials and Methods

2.1. Ethics Statement. All procedures followed were performed in strict accordance with the ethical standards of the Ethics Committee of Shandong University of Traditional Chinese Medicine Affiliated Hospital on Human Experimentation and with the Helsinki Declaration (No. KY007). Informed consent was obtained from all participants included in the study.

2.2. Disc Harvest and NP Cell Culture. As previously mentioned [24], human NP cells were isolated and cultured. Briefly, human NP samples were acquired from 12 patients (6 males and 6 females; age range: 25–70 years) with a diagnosis of idiopathic scoliosis who were undergoing surgery. NP tissues were washed three times with D-Hank’s (H1046, Solarbio, Peking, China) and cut into 1 mm³ fragments. Then, the tissues were treated with Trypsin-EDTA (0.25%; 59428C, Gibco, California, USA) for 30 min and type II collagenase (0.2%; C8150-100, Solarbio) for 4 h in a 37°C constant temperature water bath. Next, the filtered cells were transferred to DMEM/F12 containing 10% fetal bovine serum (FBS; S711-001S, Lonsera, Shanghai, China) and 1% penicillin-streptomycin (TMS-AB2, Gibco) in an incubator maintained at 37°C under a 5% CO₂ atmosphere. The complete medium was changed every 2 to 3 days. After being identified using fluorescently labeled antibody for NP cell marker CD24 (11-0247-42, Thermo Fisher Scientific, Massachusetts, USA), the second passage cells were used for all experiments.

2.3. Cell Treatment. Recombinant human TNF-α (96-300-01A, Peprotech, Rocky Hill, NJ, USA) was prepared in sterile distilled H₂O with 0.1% bovine serum albumin (BSA) and diluted in DMEM/F12 before use. Naringin (71162, Sigma-Aldrich, St. Louis, MO, USA) was directly prepared from DMSO (ST038, Beyotime Biotechnology, Shanghai, China) and diluted in DMEM/F12 to keep with 0.1% DMSO before use. The NPCs were exposed to the following treatments: (1) control group: DMEM/F12; (2) DMSO group: DMEM/F12 containing 0.1% DMSO; (3) TNF-α group: DMEM/F12 with TNF-α (50 ng/mL) containing 0.1% DMSO; (4) naringin group: DMEM/F12 with naringin (10 μg/mL) containing 0.1% DMSO; (5) TNF-α+naringin group: DMEM/F12 with TNF-α (50 ng/mL) and naringin (10 μg/mL) containing 0.1% DMSO; (6) TNF-α+naringin+3-MA (autophagy inhibitor; S2767, Selleck, Texas, USA) group: DMEM/F12 with TNF-α (50 ng/mL), naringin (10 μg/mL), and 3-MA (10 μM) containing 0.1% DMSO; (7) TNF-α+naringin+BML-275 (AMPK inhibitor; S7840, Selleck) group: DMEM/F12 with TNF-α (50 ng/mL), naringin (10 μg/mL), and BML-275 (100 μM) containing 0.1% DMSO; and (8) TNF-α+naringin+sirt1-sirNA group: DMEM/F12 with TNF-α (50 ng/mL), naringin (10 μg/mL), and SIRT1-siRNA containing 0.1% DMSO. Every group contains 0.1% DMSO except the control group.

 NP cells were exposed to TNF-α (50 ng/mL) for 24 h to induce oxidative stress or were pretreated with naringin (10 μg/mL) for 24 h alone or in combination with 3-MA (10 μM) or BML-275 (100 μM) for 2 h prior to treatment with TNF-α (50 ng/mL) for a further 24 h. For TNF-α+naringin+sirt1-sirNA group, NP cells were transfected for 24 h with 100 pM siRNA against SIRT1 using Lipofectamine 2000 or were pretreated with naringin (10 μg/mL) for 24 h alone.

2.4. Cell Viability Assay. The viability of the NP cells was evaluated by a Cell Counting Kit-8 (CKC-8; CK04, Dojindo Laboratories, Tokyo, Japan) assay in accordance with the manufacturer’s instructions. Briefly, 8 × 10⁴ cells/well were seeded in 96-well plates and treated with naringin and
TNF-α after cell adhesion as described above. At the indicated time, all NP cells collected were washed with phosphate-buffered saline (PBS, Beyotime Biotechnology). Then, 100 μL of DMEM/F12 containing 10 μL of CCK-8 solution was added to the cells in each well followed by incubation for 2 h at 37°C. After that, the OD was measured at 450 nm using an automatic plate reader (Bio-Tek ELx808TM, Vermont, USA).

2.5. ROS Assay. After various treatments, ROS production in NP cells was detected by a ROS assay kit (S0033S, Beyotime Biotechnology) according to the manufacturer’s protocol. Cells were mixed with 1 mL of diluted DCFH-DA at 37°C for 20 min. The residual DCFH-DA liquid was removed after the cells were washed with PBS three times. The expression of green fluorescence was observed under a fluorescence microscope (Olympus IX71, Tokyo, Japan).

2.6. Superoxide Dismutase (SOD) Assay. SOD activity was measured using the SOD Typed Colorimetric Assay Kit (E-BC-K022-M, Elabsience Biotechnology, Wuhan, China). First, cell culture medium was collected and incubated with different test compounds according to the manufacturer’s protocol. Next, an automatic plate reader (Bio-Tek ELx808TM) was used to read the absorbance of each sample at 550 nm. The absorbance value representing the intracellular SOD concentration of the tested NP cells.

2.7. ATP Assay. The intracellular ATP level was measured by using the colorimetric luminescence method using an ATP assay kit (E-BC-K022-M, Elabsience Biotechnology). Treated and untreated cell samples were prepared. Then, ATP was extracted from NP cells with ATP extraction reagent to determine at 636 nm using an automatic plate reader (Bio-Tek ELx808TM). The relative luminescence value represented the intracellular SOD concentration of the tested NP cells.

2.8. Mitochondrial Membrane Potential (ΔΨm) Assay. ΔΨm changes in human NP cells were assessed using an JC-1 Assay Kit (C2003S, Beyotime Biotechnology). Briefly, collected cells after indicated treatments were incubated with an equal volume of JC-1 staining solution (5 μg/mL) at 37°C for 20 min and rinsed twice with JC-1 staining buffer (1x). ΔΨm changes were monitored by determining the relative amounts of two emissions from mitochondrial JC-1 monomers or aggregates using a flow cytometry (BD Biosciences, New Jersey, USA).

2.9. MitoTracker Detection. MitoTracker staining (C1049B, Beyotime Biotechnology) was performed to visualize bioactive mitochondria and mitochondrial membrane potential changes in the human NP cells. NP cells were induced in 24-well plates according to the experimental protocol. The next step, the stained NP cells were incubated with MitoTracker Red CMXRos fluorescent dye. The expression of MitoTracker Red and green CMXRos fluorescence was detected under a fluorescence microscope (Olympus IX71). Those living cells were marked as red fluorescence that maintain mitochondrial membrane potential while others were marked as green fluorescence that have undergone apoptosis or necrosis.

2.10. Apoptosis Detection. NP cells from each treatment group were labeled by double staining using an Annexin-V/PI Apoptosis Detection Kit (C10625S, Beyotime Biotechnology). According to the experimental protocol, 6 x 10⁶ suspended cells were collected for each cell sample. Five hundred microliters of diluted 1×Annexin-V binding buffer was added to the NP cells. Then, 5 μL of Annexin-V-FITC staining solution and 5 μL of nuclear DNA staining solution were added to the cell suspension. After mixing by gently vortexing, the cells were incubated at room temperature in the dark for 15~20 min. Those cells were immediately detected with flow cytometry (BD Biosciences) after the reaction.

2.11. pH Measurements. Cultured NP cells (5 x 10⁵/mL) were seeded in 6-well plates. Upon request, NP cells were treated with drugs for 24 h until the cells reached 80% confluence. And NP cell culture medium from each treatment group was harvested, and extracellular pH (pHe) values were assessed by pH-indicator paper (1.09557, Sigma-Aldrich) and pH meter (SX5150, Sanxin, Shanghai, China) and compared with those of the control.

2.12. Alcian Blue Staining. The glycosaminoglycan production of the NP cells was measured using an Alcian Blue Stain Kit (G1560, Solarbio) according to the manufacturer’s instructions. Briefly, NP cells were first fixed with 4% paraformaldehyde for 40 min. After 5 min of nuclear fast red staining, alcian acidification solution (alcian acidification solution: distilled water = 1 : 2) was added to the cells to soak for 5 min. Then, Alcian staining solution was added to the dye for 30 min. Finally, the cells on cover slips were observed and photographed under an inverted microscope (Leica DMII, Wetzlar, Germany).

2.13. Collagen II Immunocytochemical Staining. All collected NP cells were cultured in 6-well plates with coverslips at 1 x 10⁵ cells/mL, treated as mentioned above and fixed with fresh 4% paraformaldehyde for 40 min. Then, the NP cells were incubated with 0.3% Triton X-100 (ST795, Beyotime Biotechnology) for 20 min. The samples were blocked with 5% bovine serum albumin for 60 min. The cells were then incubated with the primary antibody in proportion against collagen II (GB11022, 1 : 200, Servicebio, Wuhan, China) at 4°C overnight. After incubation with the primary antibody, a secondary antibody was diluted in proportion (GB23303, 1 : 1000, Servicebio) and added to the cells for 30 min. The cells were then incubated with DAB reagent for 10 min followed by hematoxylin staining for 20 s at room temperature. After washing with PBS, the stained NP cells were examined and imaged using an inverted microscope (Leica DMII).
2.14. Transmission Electron Microscopy (TEM). In order to observe the ultrastructure of the autophagosomes and autolysosomes, second passage NP cells were fixed in 2.5% glutaraldehyde solution for 12 h after treatment and then fixed again with 1% osmium acid. Following gradient dehydration with a series of ethanol and acetone solutions, the cells were embedded in epoxy resin, and the selected areas were cut into 70 nm ultrathin sections. The cells were then stained with lead citrate and uranium acetate. Subsequently, all of the ultrathin sections were observed under a TEM (JEM-ARM200F, Tokyo, Japan) to calculate the number of autophagosomes.

2.15. pAV-CMV-TagRFP-SEP-LC3 Assay. To estimate the efficiency of autophagic flux, the NP cells were dealt with pAV-CMV-TagRFP-SEP-LC3 recombinant adenovirus vectors (S2231, Sunbio Medical Biotech Co., Ltd., Shanghai, China). First, the cells were inoculated in 24 aperture plates with a density of $1 \times 10^5$ cells/mL. Next, the pAV-CMV-TagRFP-SEP-LC3 recombinant adenovirus titer of the original solution was diluted to $1 \times 10^8$ PFU/mL with PBS. When the MOI = 100, the transfection efficiency was the best. A precalculated adenovirus volume was added to the cells for 24 h. On the following day, the existing culture medium was replaced and the designated drug was added. After
treatment, the cells were observed and measured by the laser-scanning confocal microscope (Dragonfly200, Andor, UK). As discussed earlier [25], autophagosomes appear as yellow spots, but autolysosomes appear as red spots. With increase of the autophagic flux, both yellow and red spots increase correspondingly. But while autophagic flux is blocked, yellow spots are increased but red spots are kept also.

2.16. TUNEL Staining. To examine the apoptosis of human NP cells in each indicated group, cells were stained with a One-Step TUNEL Apoptosis Assay Kit (C1088; Beyotime Biotechnology). Briefly, the cultured NP cells were prepared in a 6-well plate. After treatment, these cells were fixed with freshly prepared 4% paraformaldehyde for 1 h, incubated with 0.1% Triton X-100 for 10 min, and washed with PBS three times in every step. According to the manufacturer’s instructions, cells were stained with an in situ cell death detection kit. Apoptotic changes were measured under a fluorescence microscope (Olympus IX71).

2.17. Immunofluorescence Staining. Expression of matrix macromolecules (collagen II; ab283694, Abcam, Cambridge, UK) and catabolism enzymes (MMP-3; ab137659, Abcam) and autophagy-related markers (LC3; ab128025, Abcam) was analyzed by immunofluorescence. NP cells were fixed to glass coverslips with 4% paraformaldehyde (P0099, Beyotime Biotechnology) for 40 min and then permeabilized with 0.1% Triton X-100 (ST797, Beyotime Biotechnology) for 20 min. After blocking with 0.5% BSA for 30 min, the NP cells were incubated with primary antibodies against collagen II (1 : 200) and MMP-3 (1 : 200) at 4°C overnight. The next day, the NP cells were incubated with the appropriate secondary antibody at room temperature in the dark for 60 min. After washing with PBS, the cells were incubated with DAPI at room temperature for 3 min. Fluorescence images were acquired by a fluorescence microscope (Olympus IX71).

2.18. siRNA Transfection. Before siRNA transfection, 5 × 10⁴ cells/mL were seeded in a 6-well plate. The experiment was
carried out until the cells reached 60% confluence. Human SIRT1 siRNA and the negative control siRNA (NC-siRNA) were designed and synthesized by GenePharma (Shanghai, China). A hundred pM of siRNA was mixed gently with 250 μL of Opti-MEM medium. Four microliters of diluted Lipofectamine® 2000 (11668030, Invitrogen, California, USA) reagent was gently mixed with 196 μL of Opti-MEM medium at room temperature for 5 min. The diluted siRNA and RNAi-Mate reagent was gently mixed with the siRNA/Lipofectamine® 2000 complex at room temperature for 20 min. The complex was added to the well of the culture plate, and the cell culture plate was gently shaken back and forth. After the cells were incubated at 37°C in a humidified 5% CO₂ atmosphere for 24 h, the other detection steps after transfection were carried out.

2.19. Quantitative Real-Time PCR (qRT-PCR). The expression levels of MMP-3 and collagen II were detected by qRT-PCR. After various treatments, the total mRNA of NP cells was extracted by the column method (AC0203, Spark jade). GAPDH was used to normalize gene expression, and complementary DNA (cDNA) was synthesized at 50°C for 30 min (AG0304, Sparkjade). The PCR conditions were as follows: denaturing at 94°C 3 times for 1 min, annealing at 60°C for 20 s, extension at 72°C for 20 s, and finally amplification once. Next, SYBR Green PCR master mix (AH0104-C, Sparkjade) on a Roche LightCycler®480 instrument (Roche, Basel, Switzerland) was further used for qRT-PCR. The synthetic primer sequences were as follows: human GAPDH (F) 5′-GAAGGTGAAGGTCGGAGTC-3′, (R) 5′-GAAGATGGTGATGGGATTTC-3′; MMP3 (F) 5′-GGGTCTCTTTCACTCAGCCAACAC-3′, (R) 5′-ACAGGCGGACCGAGTCAGG-3′; and collagen II (F) 5′-TGAAGACCCAGACTGCTTCAAA-3′, (R) 5′-CGAGGTGAGCTGGCAGAT-3′. The relative expression of RNA was calculated by the 2⁻ΔΔCT method.

2.20. Western Blot Assay. Total protein was extracted from NPCs using the RIPA buffer (P0013K, Beyotime Biotechnology) with 1 mmol/L PMSF. The protein concentration was measured using a BCA protein assay kit (P0012, Beyotime Biotechnology) and Skanit software 3.1 for Multiskan Go (Thermo Fisher Scientific). The protein extracted from each sample was electrophoretically separated on a 5–20% pre-polymerized polyacrylamide gel and transferred to a
polyvinylidene fluoride (PVDF; BS-PVDF-45-22, Biosharp, Peking, China) membrane. The membrane was blocked for 1 h with 5% nonfat milk and incubated with primary antibodies overnight at 4°C: COX-2 (1:1000; ab179800, Abcam), C-caspase-3 (1:500; ab32351, Abcam), Bax (1:1000; ab32503, Abcam), Bcl-2 (1:1000; ab32124, Abcam), LC3 (1:1000; ab128025, Abcam), Beclin-1 (1:300; ab217179, Abcam), P62 (1:1000; ab182579, Abcam), MMP-3 (1:500; ab84792, Abcam), ADAMTS-4 (1:500; ab283694, Abcam), aggrecan (1:1000; ab36861, Abcam), AMPK (1:1000; ab23875, Abcam), p-AMPK (1:1000; ab23875, Abcam), and SIRT1 (1:1000; ab7343, Abcam). Then, the membrane was incubated with horseradish peroxidase-(HRP-) bound secondary antibody (1:5000; ab7090, Abcam) for 2 h at room temperature. The membranes were visualized using a Millipore ECL chemiluminescence kit (WBKLS0100, Merck) and exposed to a autoradiographic film. Finally, target protein expression normalized to GAPDH was analyzed using ImageJ software version 1.8.0 (National Institutes of Health, USA).

2.21. Statistical Analysis. Data are presented as the means ± standard deviation (SD). All statistical analyses were performed using GraphPad Prism version 8.0.1 (GraphPad Software Inc., California, USA). Intergroup differences were analyzed by one-way analysis of variance (ANOVA), and Tukey’s test was used to compare the control group and

Figure 5: Naringin ameliorates ECM degradation in TNF-α-induced human NP cells. (a) Alcian blue staining in human NP cells under inverted microscope (scale bar: 100 μm). (b) Collagen II staining in human NP cells under inverted microscope (scale bar: 100 μm). (c, d) The protein levels of SOX-9, aggrecan, collagen II, MMP-3, and ADAMTS-4 were measured by Western blotting. The data represent the means ± SD. Significant differences between groups are indicated as *p < 0.05, **p < 0.01, and ***p < 0.001, n = 3.
the treatment group. A value of $p < 0.05$ was considered statistically significant. All experiments were performed in triplicate.

3. Results

3.1. Naringin Rescues Human NP Cells Treated with TNF-α. The chemical structure of naringin is shown in Figure 1(a). Human NP cells from all 12 cases showed high CD24+ (99.49 ± 0.19%; range 99.3–99.68%) expression under normal conditions (Figure 1(b)). In the CCK-8 assay, no marked increase in naringin cytotoxicity (0, 0.1% DMSO, 5, 10, 20, and 40 μg/mL of naringin) was detected in NP cells at 24 h (Figure 1(c)). 10 μg/mL naringin pretreatment showed the strongest protective effects against TNF-α (50 ng/mL) (Figure 1(d)). These results determined that the optimal dose of naringin for NP cell rescue was 10 μg/mL.

3.2. Naringin Attenuates TNF-α-Induced Inflammation in Human NP Cells. TNF-α, a spark for high-grade inflammation, stimulates the release of inflammatory mediators and further leads to degenerative changes [26]. In this study, elevated COX-2 levels were detectable in NP cells treated for 24 h with TNF-α, which was significantly suppressed in cells pretreated with naringin (Figure 2(a)). These data support the reliability of the TNF-α-induced inflammation model in vitro.

An acidic microenvironment is often a result of local inflammation [27]. We detected extracellular pH (pHe) to explore the anti-inflammatory properties of naringin against TNF-α. A lower pHe was observed in TNF-α-treated cells versus intact and DMSO-treated controls. But naringin pretreatment markedly elevated the pHe (Figure 2(b)). Therefore, naringin significantly counteracts the adverse effects of TNF-α on NP cells, demonstrating a robust anti-inflammatory activity in the in vitro IDD model.

3.3. Naringin Inhibits TNF-α-Induced Oxidative Stress and Mitochondrial Dysfunction in Human NP Cells. Oxidative stress activation has been implicated in excessive ROS-induced mitochondrial dysfunction and the process of IDD [25]. So we assessed intracellular $H_2O_2$ and oxidative stress...
Figure 7: Continued.
Figure 7: Continued.
The protein levels of LC3, Beclin-1, and P62 were measured by Western blotting. (a) The protein expressions of Collagen II and MMP-3 were measured by qRT-PCR. (b) The variation of autphagic flux was detected by confocal microscope (yellow spots represent autophagosomes, red spots represent autolysosomes). (c) TUNEL staining results to detect the rate of apoptosis in human NP cells. (d) The ratio of CollagenII/GAPDH (of control) was significantly increased in TNF-α-treated NP cells versus intact and DMSO-treated controls. Naringin markedly increased LC3-II/I ratio and ATP synthesis is evidence of mitochondrial dysfunction. TNF-α treatment led to a loss of ΔΨm and reduced ATP levels in human NP cells (Figures 3(d) and 3(c)). Naringin partially restored the deficiency in TNF-α-treated cells.

3.5. Naringin Ameliorates ECM Degradation in TNF-α-Treated Human NP Cells. IDD is mostly associated with the disequilibrium of ECM synthesis and degradation primarily mediated by matrix metalloproteinase (MMP) enzymes and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS). We utilized the Alcian blue staining and collagen II immunohistochemistry to assess changes in ECM components. The results showed that TNF-α stimulation pronouncedly suppressed the synthesis of aggrecan (one of the most important structural proteoglycans) and collagen II (Figures 5(a) and 5(b)). The expressions of collagen II biomarkers, aggrecan and SOX-9 (for cartilage synthesis), were markedly inhibited by TNF-α. However, MMP3 and ADAMTS-4 expressions were enhanced after TNF-α administration (Figures 5(c) and 5(d)), indicating TNF-α-induced ECM loss. These aberrant expressions of ECM components were dramatically reversed by naringin.

3.6. Naringin Upregulates Autophagic Flux in Human NP Cells via Autophagy Activation. We assessed the expressions of the autophagy-related markers LC3 and Beclin-1 using Western blot to explore whether single-use naringin could protect NP cells via inducing autophagy. P62 is a specific substrate degraded in autolysosomes. P62 protein levels were quantitated in this study to explore the impairment of autophagic flux. Naringin markedly increased LC3-II/I ratio and Beclin-1 expression and inhibited p62 expression in TNF-α-treated NP cells versus intact and DMSO-treated controls (Figure 6(c)), indicating ameliorated autophagy. This finding was also supported by the enhanced fluorescence intensity of LC3 (Figure 6(b)). The TEM observation showed that more autophagosomes were observed in cells treated with naringin compared to the TNF-α group, indicating that naringin potently restores mitochondrial function and NP cell activity.
pretreated with naringin (Figure 6(a)). All these results suggest that naringin triggers autophagy and promotes autophagic flux in NP cells.

3.7. The Protective Effects of Naringin Are Reversed by Autophagic Flux Inhibition. The autophagy inhibitor 3-MA was used to ascertain whether naringin’s protection against TNF-α-induced IDD depended on autophagy stimulation. As shown in Figure 7(a), TNF-α partially increased LC3-II/LC3-I and Beclin-1 expressions and p62 expression. This may be related to NP cell defenses against pathological lesion via enhancing autophagy in the damaged areas through reutilizing their substances for energy. The pAV-CMV-TagRFP-SEP-LC3 assay revealed an increased number of yellow spots rather than red spots in TNF-α-treated cells, suggesting impaired autophagic flux (Figure 7(b)). Naringin induced an increment in autophagic flux under TNF-α exposure, but intriguingly, the protective effects of naringin were partially offset by 3-MA. So naringin may inhibit TNF-α via restoring autophagic flux for protection.

We next investigated whether these benefits from naringin-induced autophagy could ascribe to the efficient rebalancing of cell apoptosis and ECM degeneration in human NP cells treated with TNF-α. We detected apoptosis-related proteins and found that naringin repressed proapoptotic C-caspase-3 and Bax expressions that had elevated by TNF-α but increased Beclin-2 expression (Figure 7(d)). In the TUNEL staining, naringin suppressed the green fluorescence intensity once enhanced by TNF-α (Figure 7(c)), but this effect was counteracted by 3-MA. Also, 3-MA inhibited the expressions of collagen II biomarkers that had been improved and corrected the low MMP-3 expression in naringin-treated cells (Figures 7(e)–7(i)). These results indicate that 3-MA inhibits already ameliorated autophagic flux by naringin, canceling the benefits from naringin treatment (Figure 7).
3.8. Naringin-Mediated Autophagy Is Activated by the AMPK/SIRT1 Signaling in Human NP Cells. Since the AMPK/SIRT1 signaling has been shown to have the greatest therapeutic potential for IDD, we explored whether it could be responsible for naringin-induced autophagy in TNF-α-treated NP cells. The phosphor AMPK (p-AMPK) expression significantly increased in cells pretreated with naringin, whose p-AMPK/AMPK ratio could be suppressed by the AMPK inhibitor BML-275 (Figure 8(a)). Naringin elevated LC3 and Beclin-1 expressions, together with a lower p62 level and a rising p-AMPK/AMPK ratio in NP cells. However, the enhanced autophagy activity by naringin was further depressed after the addition of BML-275 (Figure 8(b)).

As for the potential roles of SIRT1, the most significant downstream component of AMPK, we knocked down the SIRT1 gene by siRNA transfection. SIRT1 expression significantly decreased in negative controls and transfected cells pretreated with naringin compared to high SIRT1 expression in untransfected cells pretreated with naringin (Figure 9(a)). The high SIRT1 expression in naringin-treated untransfected cells was dramatically inhibited by the AMPK inhibitor BML-275 (Figures 9(a) and 9(b)). These findings suggest that naringin may activate autophagy activity via AMPK/SIRT1 activation (Figure 10).

4. Discussion
IDD often occurs prior to other musculoskeletal symptoms. It is reported that an estimated 20% of teens have developed mild-degenerated discs [3]; IDD often increases with age, and this trend is particularly apparent in males. Besides, 10% of 50-year-olds and 60% of 70-year-olds are found to have severe IDD [32]. Currently, the underlying mechanisms and treatment scenarios for IDD remains rather limited, despite the continuing impacts of this disease on life quality. Identification of active ingredients against IDD
progression is urgently needed [25]. Naringin is a natural anti-inflammatory compound comprised of various pharmacological activities capable of dealing with degenerative-related diseases [23, 33, 34]. In the current study, we explored the mechanisms responsible for naringin’s protection against TNF-α in an in vitro IDD model and ascertained that naringin-induced autophagic flux increment suppresses inflammation response, oxidative stress, cell apoptosis, and ECM degradation induced by TNF-α via AMPK/SIRT1 activation in human NP cells.

It is widely accepted that very few mitochondria are present in NP cells due to a physiologically avascular and hypoxic niche therein. However, Madhu et al. reported abundant mitochondria in NP cells based on in vivo and in vitro experiments [35]. ROS production (including $\cdot$O$_2^-$, H$_2$O$_2$, and $\cdot$OH) is required in oxidative metabolism to produce ATP in mitochondria. Mitochondrial SOD converts $\cdot$O$_2^-$ into H$_2$O$_2$, and the latter is translated by catalase into harmless H$_2$O to maintain the antioxidant/oxidative balance of cells [27]. Nevertheless, an extracellular concentration of H$_2$O$_2$ may increase 10 to 100 times in response to inflammation [36]. TNF-α has been considered the culprit cytokine that triggers an inflammatory cascade [4, 9] via promoting the secretion of inflammatory mediators such as cyclooxygenase-2 (COX-2) in IDD [25]. Thus, we established the IDD model in vitro using TNF-α. In the present study, TNF-α significantly increased COX-2 levels, enhancing inflammation in human NP cells. It also elevated ROS and ATP production, SOD activity, and mitochondrial membrane potential, hallmarks of extensive oxidative stress in cells. In addition, extracellular pH was slightly inhibited after TNF-α exposure, creating a dynamic acidic niche in response to inflammation. This can also be explained by disrupted Ca$^{2+}$ homeostasis under oxidative stress [37]. All of these were potently attenuated by naringin pretreatment.

Loss of biochemical homeostasis in NP cells leads to cell apoptosis, exacerbating IDD [3]. Two apoptotic pathways, the mitochondrial (intrinsic) and death receptor (extrinsic) pathways, have been identified. For the former, oxidative stress contributes to cell apoptosis, leading to the imbalance between proapoptotic Bax and antiapoptotic Bcl-2, further stimulating caspase-3 activation and thereby accelerating NP cell apoptosis [38]. For the latter, extracellular TNF-α activates the effector caspase-3 to unleash intracellular apoptosis signals via the death receptor-mediated pathway [29]. In the present study, our findings demonstrated that TNF-α aggravates cell apoptosis in NP cells via a combination of the intrinsic and extrinsic pathways, whereas this damaging effect was overturned by naringin pretreatment.

Excessive apoptosis in NP cells directly breaks the dynamic balance between the ECM destruction and synthesis [39]. Normally, the two predominant ECM components, aggrecan (covalently attaching highly anionic glycosaminoglycans) and collagen II, are responsible for cellular...
homeostasis. Further, SOX-9 has been proven to have a positive correlation with the number of NP cells and the presence of ECM. These resident cells, though limited (approximately 5,000 cells/mm³), are responsible for producing ECM and maintaining the integrity of the IVD [32]. Furthermore, numerous biomarkers for matrix-degrading enzymes (e.g., MMPs and ADAMTSs) play a crucial role in ECM degradation [39]. We found that naringin suppressed MMP-3 and ADAMTS-4 expressions and retained the matrix components by promoting type II collagen contents and aggrecan and SOX-9 expressions in TNF-α-treated NP cells, demonstrating its strong effect of protecting against ECM degeneration.

Autophagy degrades damaged organelles and proteins for nutrient recycling. During autophagy, Beclin-1 participates in the nucleation of the autophagosomal membrane [40], and LC3-II is involved in double-membrane vesicle formation and the elongation of the autophagosomal membrane [41], which are considered the biomarkers for autophagy initiation. In autophagosomes, p62 serves as a substrate to be degraded in the autophagy-lysosome system via binding to ubiquitinated proteins. Accordingly, it is often used as a marker for autophagy degradation. However, there is a debate regarding autophagy biomarkers and their functions in IDD. Ye et al. reported significantly increased Beclin-1 and LC3-II/LC3-1 protein expressions in IDD rats versus normal controls, supporting autophagy-induced IDD progression [42]. But most in vitro and in vivo experiments demonstrated a positive role of autophagy in IDD [43–45]. Liao et al. found that lipopolysaccharide-induced pyroptosis of human NP cells was relieved via autophagy-based unconventional secretory pathway stimulated by the autophagy inducer rapamycin compared to aggravated pyroptosis in cells treated with 3-MA [43]. Li et al. showed that autophagy activation decreased the expression of absent in melanoma 2 (AIM2) inflammasome against cellular DNA damage in rat NP cells via the autophagy-lysosome pathway [44]. Therefore, multiple autophagic signalings are involved in the pathogenesis of IDD. Blockade of autophagic flux impairs autophagosomal function and disrupts homeostasis of NP cell, thus initiating cell apoptosis [45]. The restoration of autophagy or autophagic flux for NP cell rescue or preventing IDD progression has been frequently demonstrated [24]. Therefore, protection against IDD can be autophagy-dependent.

Naringin is a natural flavonoid that has been confirmed to both stimulate and inhibit autophagy activity in many types of cells [46–48]. In this study, naringin induced autophagy increment and restored autophagic flux in human NP cells. Blocking autophagic flux by 3-MA sparked cell apoptosis and ECM component degradation in NP cells. All these support autophagy-mediated protection of naringin against NP cell death and IDD progression.

AMPK is a key energy sensor ubiquitous in eukaryotes and initiates autophagy to maintain energy homeostasis. During oxidative stress induced by ischemia and hypoxia, insufficient ATP supply, and the resultant high AMP content stimulate AMPK phosphorylation [49, 50], which activates numerous downstream substrates to inhibit ATP consumption and boost ATP production to maintain energy homeostasis. It also increases intracellular NAD⁺ levels to activate NAD⁺-dependent SIRT1 [51]. IVD pressure and nutrition are closely associated with AMPK/SIRT1-mediated restoration of autophagy in NP cells. In our study, naringin stimulated p-AMPK and SIRT1 expressions alongside elevated LC3 and Beclin-1 and lowered p62, which were offset, together with impaired autophagic flux, by the AMPK inhibitor EX-527 or SIRT1 silencing. So naringin protects against IDD through autophagy restoration via activation of the AMPK/SIRT1 signaling.

Some limitations are apparent. A single dose of naringin was insufficient for studying its efficacy. Multiple doses of naringin tested at several time points are required in our future studies. The roles of the autophagic AMPK/SIRT1 signaling were merely validated in vitro. Animal experiments for stronger evidence will be undertaken in the future publications in a timely manner. Furthermore, this study primarily focused on whether naringin’s protection against IDD was autophagy-dependent and relevant mechanisms, rather than impaired biochemical homeostasis induced by proinflammatory cytokines and the potential mechanisms for the effect of naringin on rescuing it. However, the latter also deserves thorough exploration for a better understanding of this disease.

5. Conclusion

Naringin boosts autophagic flux through SIRT1 upregulation via AMPK activation, thus protecting NP cells against inflammatory response, oxidative stress, and impaired cellular homeostasis. Naringin seems a promising inducer for restoration of autophagic flux for IDD.

Abbreviations

| Acronym | Description |
|---------|-------------|
| IVD     | Intervertebral disc |
| NP      | Nucleus pulposus |
| ECM     | Extracellular matrix |
| IDD     | Intervertebral disc degeneration |
| LBP     | Low back pain |
| TNF-α   | Tumor necrosis factor-α |
| ROS     | Reactive oxygen species |
| AMPK    | AMP-activated protein kinase |
| SIRT1   | Silent information regulator-1 |
| 3-MA    | 3-Methyladenine |
| MMP-3   | Matrix metalloproteinase-3 |
| ADAMTS-4| A disintegrin and metalloproteinase with thrombospondin motifs-4 |
| COX-2   | Cyclooxygenase-2 |
| SOD     | Superoxide dismutase |
| AIM2    | Absent in melanoma 2 |

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.
Conflicts of Interest

The authors declare that they have no conflict of interest.

Acknowledgments

The author thanks tutor Nianhu Li and laboratory teachers of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine for their careful guidance. We also thank my girlfriend Shuhan Hu for revising the manuscript. This work is supported by the Natural Science Foundation of Shandong Province (ZR2019MH044), the Shandong Science and Technology Project of College and University (J17KA242), the Sixth Batch of Academic Experience Inheritance Project of the National Experts of Traditional Chinese Medicine ([2017] No. 29), and the Xu Zhanwang Shandong Construction Project of Inheritance Studio for Famous and Old TCM Experts ([2019] No. 92).

References

[1] X. Cheng, L. Zhang, K. Zhang et al., “Circular RNA VMA21 protects against intervertebral disc degeneration through targeting miR-200c and X-linked inhibitor-of-apoptosis protein,” *Annals of the Rheumatic Diseases*, vol. 77, no. 5, pp. 770–779, 2018.

[2] A. N. Khan, H. E. Jacobsen, J. Khan et al., “Inflammatory biomarkers of low back pain and disc degeneration: a review,” *Annals of the New York Academy of Sciences*, vol. 1410, no. 1, pp. 68–84, 2017.

[3] C. Ruiz-Fernández, V. Francisco, J. Pino et al., “Molecular relationships among obesity, inflammation and intervertebral disc degeneration: are adipokines the common link?,” *International Journal of Molecular Sciences*, vol. 20, no. 8, p. 2030, 2019.

[4] P. A. Hernandez, T. D. Jacobsen, and N. O. Chahine, “Actomyosin contractility confers mechanoprotection against TNFα-induced disruption of the intervertebral disc,” *Science Advances*, vol. 6, no. 34, 2020.

[5] Z. Liao, X. Wu, Y. Song et al., “Angiopoietin-like protein 8 expression and association with extracellular matrix metabolism and inflammation during intervertebral disc degeneration,” *Journal of Cellular and Molecular Medicine*, vol. 23, no. 8, pp. 5737–5750, 2019.

[6] J. Hartvigsen, M. J. Hancock, A. Kongsted et al., “What low back pain is and why we need to pay attention,” *The Lancet*, vol. 391, no. 10137, pp. 2356–2367, 2018.

[7] S. Yang, F. Zhang, J. Ma, and W. Ding, “Intervertebral disc aging and degeneration: the antiapoptotic effect of oestrogen,” *Aging Research Reviews*, vol. 57, 2020.

[8] P. Cazzanelli and K. Wuertz-Kozak, “MicroRNAs in intervertebral disc degeneration, apoptosis, inflammation, and mechanobiology,” *International Journal of Molecular Sciences*, vol. 21, no. 10, p. 3601, 2020.

[9] C. Weller, A. G. Nerlich, B. E. Bachmeier, and N. Boos, “Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: a study in surgical specimens and autopsy controls,” *Spine*, vol. 30, no. 1, pp. 44–53, 2005.

[10] Y. Zhang, Y. Zhao, J. Li et al., “Interleukin-9 promotes TNF-α and PGE2 release in human degenerated intervertebral disc tissues,” *Spine*, vol. 41, no. 21, pp. 1631–1640, 2016.

[11] S. E. Navone, M. Peroglio, L. Guaraccia et al., “Mechanical loading of intervertebral disc modulates microglia proliferation, activation, and chemotaxis,” *Osteoarthritis and Cartilage*, vol. 26, no. 7, pp. 978–987, 2018.

[12] H. Yu, G. Hou, J. Cao, Y. Yin, Y. Zhao, and L. Cheng, “Mangiferin alleviates mitochondrial ROS in nucleus pulposus cells and protects against intervertebral disc degeneration via suppression of NF-κB signaling pathway,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 6632786, 27 pages, 2021.

[13] X. Li, F. Lin, Y. Wu et al., “Resveratrol attenuates inflammation environment-induced nucleus pulposus cell senescence in vitro,” *Bioscience Reports*, vol. 39, no. 5, 2019.

[14] C. Feng, M. Yang, M. Lan et al., “ROS: crucial intermediators in the pathogenesis of intervertebral disc degeneration,” *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 5601593, 12 pages, 2017.

[15] L. Galluzzi and D. R. Green, “Autophagy-independent functions of the autophagy machinery,” *Cell*, vol. 177, no. 7, pp. 1682–1699, 2019.

[16] Y. Liu and B. Levine, “Autosis and autophagic cell death: the dark side of autophagy,” *Cell Death and Differentiation*, vol. 22, no. 3, pp. 367–376, 2015.

[17] S. Song, S. Bao, C. Zhang et al., “Stimulation of AMPK prevents diabetes-induced photoreceptor cell degeneration,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 5587340, 15 pages, 2021.

[18] K. Zhang, X. Zhou, J. Wang et al., “Dendrobiyum officinale polysaccharide triggers mitochondrial disorder to induce colon cancer cell death via ROS-AMPK-autophagy pathway,” *Carbohydrate Polymers*, vol. 264, 2021.

[19] J. Yang, H. Suo, and J. Song, “Protective role of mitoquinone against impaired mitochondrial homeostasis in metabolic syndrome,” *Critical Reviews in Food Science and Nutrition*, vol. 61, no. 22, pp. 3857–3875, 2021.

[20] W. Jia, T. Bai, J. Zeng et al., “Combined administration of metformin and atorvastatin attenuates diabetic cardiomyopathy by inhibiting inflammation, apoptosis, and oxidative stress in type 2 diabetic mice,” *Frontiers in Cell and Developmental Biology*, vol. 9, 2021.

[21] S. Regmi, P. K. Raut, S. Pathak, P. Shrestha, P. H. Park, and J. H. Jeong, “Enhanced viability and function of mesenchymal stromal cell spheroids is mediated via autophagy induction,” *Autophagy*, vol. 17, no. 10, pp. 2991–3010, 2021.

[22] A. H. El-Desoky, R. F. Abdel-Rahman, O. K. Ahmed, H. S. El-Beltagi, and M. Hattori, “Anti-inflammatory and antioxidant activities of naringin isolated from *Carissa carandas L.: In vitro and in vivo* evidence,” *Phytomedicine*, vol. 42, pp. 126–134, 2018.

[23] H. Zhao, M. Liu, H. Liu, R. Suo, and C. Lu, “Naringin protects endothelial cells from apoptosis and inflammation by regulating the Hippo-YAP pathway,” *Bioscience Reports*, vol. 40, no. 3, 2020.

[24] N. Li, C. Whitaker, Z. Xu, M. Heggeness, and S. Y. Yang, “Therapeutic effects of naringin on degenerative human nucleus pulposus cells for discogenic low back pain,” *The Spine Journal*, vol. 16, no. 10, pp. 1231–1237, 2016.

[25] L. Kang, Q. Xiang, S. Zhan et al., “Restoration of autophagic flux rescues oxidative damage and mitochondrial dysfunction
Oxidative Medicine and Cellular Longevity
to protect against intervertebral disc degeneration,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 7810320, 27 pages, 2019.

[26] Z. Yu, L. Ma, S. Ye, G. Li, and M. Zhang, “Construction of an environmentally friendly octenylsuccinic anhydride modified pH-sensitive chitosan nanoparticle drug delivery system to alleviate inflammation and oxidative stress,” Carbohydrate Polymers, vol. 236, 2020.

[27] S. Wang, J. Wei, J. Shi et al., “Follistatin-like 1 attenuation suppresses intervertebral disc degeneration in mice through interacting with TNF-α and Smad signaling pathway,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 6640751, 13 pages, 2021.

[28] J. M. Suski, M. Lebiedzinska, M. Bonora, P. Pinton, J. Duszynski, and M. R. Wieckowski, “Relation between mitochondrial membrane potential and ROS formation,” Methods in Molecular Biology, vol. 810, pp. 183–205, 2012.

[29] V. Vasquez-Montes, M. V. Rodnin, A. Kyrchenko, and A. S. Ladokhin, “Lipids modulate the BH3-independent membrane targeting and activation of BAX and Bcl-xl,” Proceedings of the National Academy of Sciences of the United States of America, vol. 118, no. 37, 2021.

[30] R. Zhao, W. Liu, M. Wang et al., “Lysyl oxidase inhibits TNF-α induced rat nucleus pulposus cell apoptosis via regulating Fas/FasL pathway and the p53 pathways,” Life Sciences, vol. 260, 2020.

[31] L. Xiao, M. Ding, A. Fernandez, P. Zhao, L. Jin, and X. Li, “Curcumin alleviates lumbar radiculopathy by reducing neuroinflammation, oxidative stress and nociceptive factors,” European Cells & Materials, vol. 33, pp. 279–293, 2017.

[32] P. P. Raj, “Intervertebral disc: anatomy-physiology-pathophysiology-treatment,” Pain Practice, vol. 8, no. 1, pp. 18–44, 2008.

[33] L. Pedro, M. Gaspar Vitor, and J. F. Mano, “Bioinspired bone therapies using naringin: applications and advances,” Drug Discovery Today, vol. 23, no. 6, pp. 1293–1304, 2018.

[34] L. Wang, Y. G. Zhang, X. M. Wang, L. F. Ma, and Y. M. Zhang, “Naringin protects human adipose-derived mesenchymal stem cells against hydrogen peroxide-induced inhibition of osteogenic differentiation,” Chemico-Biological Interaction, vol. 242, pp. 255–261, 2015.

[35] V. Madhu, P. K. Boneski, E. Silagi et al., “Hypoxic regulation of mitochondrial metabolism and mitophagy in nucleus pulposus cells is dependent on HIF-1α–BNIP3 axis,” Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research, vol. 35, no. 8, pp. 1504–1524, 2020.

[36] X. Liu, D. E. Cooper, A. A. Cluntun et al., “Acetate production from glucose and coupling to mitochondrial metabolism in mammals,” Cell, vol. 175, no. 2, pp. 502–513.e13, 2018.

[37] Q. Sun, B. Liu, R. Zhao et al., “Calcium peroxide-based nanosystem with cancer microenvironment-activated capabilities for imaging guided combination therapy via mitochondrial Ca2+ overload and chemotherapy,” ACS Applied Materials & Interfaces, vol. 13, no. 37, pp. 44096–44107, 2021.

[38] Y. Zhao, C. Qiu, W. Wang et al., “Cortistatin protects against intervertebral disc degeneration through targeting mitochondrial ROS-dependent NLRP3 inflammasome activation,” Theranostics, vol. 10, no. 15, pp. 7015–7033, 2020.

[39] J. Bao, Z. Qian, L. Liu, X. Hong, H. Che, and X. Wu, “Pharmacological disruption of phosphorylated eukaryotic initiation factor-2/α-activating transcription factor 4/Indian hedgehog protects intervertebral disc degeneration via reducing the reactive oxygen species and apoptosis of nucleus pulposus cells,” Frontiers in cell and developmental biology, vol. 9, article 675486, 2021.

[40] N. Mizushima and B. Levine, “Autophagy in human diseases,” The New England Journal of Medicine, vol. 383, no. 16, pp. 1564–1576, 2020.

[41] D. Fracchiolla, J. Sawa-Makarska, and S. Martens, “Beyond Atg8 binding: the role of AIM/LIR motifs in autophagy,” Autophagy, vol. 13, no. 5, pp. 978–979, 2017.

[42] W. Ye, W. Zhu, K. Xu et al., “Increased macroautophagy in the pathological process of intervertebral disc degeneration in rats,” Connective Tissue Research, vol. 54, no. 1, pp. 22–28, 2013.

[43] Z. Liao, S. Li, R. Liu et al., “Autophagic degradation of gasdermin D protects against nucleus pulposus cell pyroptosis and retards intervertebral disc degeneration in vivo,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 5584447, 22 pages, 2021.

[44] S. Li, Z. Liao, R. Luo et al., “Autophagy-based unconventional secretory for AIM2 inflammasome drives DNA damage resistance during intervertebral disc degeneration,” Frontiers in Cell and Developmental Biology, vol. 9, 2021.

[45] J. Lin, J. Zhuge, X. Zheng et al., “Urolithin A-induced mitophagy suppresses apoptosis and attenuates intervertebral disc degeneration via the AMPK signaling pathway,” Free Radical Biology & Medicine, vol. 150, pp. 109–119, 2020.

[46] S. Li, J. Jiang, J. Fang et al., “Naringin protects H9C2 cardiomyocytes from chemical hypoxia-induced injury by promoting the autophagic flux via the activation of the HIF-1α/BNIP3 signaling pathway,” International Journal of Molecular Medicine, vol. 47, no. 6, 2021.

[47] G. Xingtao and Z. Gang, “Protective effects of naringin on glucocorticoid-induced osteoporosis through regulating the PI3K/Akt/mTOR signaling pathway,” American Journal of Translational Research, vol. 13, no. 6, pp. 6330–6341, 2021.

[48] J. Feng, X. Chen, S. Lu et al., “Naringin attenuates cerebral ischemia-reperfusion injury through inhibiting peroxynitrite mediated mitophagy activation,” Molecular Neurobiology, vol. 55, no. 12, pp. 9029–9042, 2018.

[49] D. Carling, “AMPK signalling in health and disease,” Current Opinion in Cell Biology, vol. 45, pp. 31–37, 2017.

[50] I. P. Salt and D. G. Hardie, “AMP-activated protein kinase,” Circulation Research, vol. 120, no. 11, pp. 1825–1841, 2017.

[51] A. Cattelan, G. Ceolotto, S. Bova et al., “NAD+-dependent SIRT1 deactivation has a key role on ischemia-reperfusion-induced apoptosis,” Vascular Pharmacology, vol. 70, pp. 35–44, 2015.